☰

Anagha Nadkarni, Ph.D. - Publications

Affiliations: 
2009 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Pharmacy
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

46 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL. Correction to: Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population. Journal of Thrombosis and Thrombolysis. PMID 32564179 DOI: 10.1007/S11239-020-02161-0  0.34
2020 Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy. 26: 639-651. PMID 32347184 DOI: 10.18553/Jmcp.2020.26.5.639  0.395
2019 Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Nadkarni A, Shank TC. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. Bmc Cardiovascular Disorders. 19: 142. PMID 31195999 DOI: 10.1186/S12872-019-1116-1  0.354
2019 Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. Journal of the American Geriatrics Society. PMID 31112292 DOI: 10.1111/Jgs.15956  0.363
2019 Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. Plos One. 14: e0213614. PMID 30908512 DOI: 10.1371/Journal.Pone.0213614  0.332
2018 Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke. 49: 2933-2944. PMID 30571400 DOI: 10.1161/Strokeaha.118.020232  0.375
2018 Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A. Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Advances in Therapy. PMID 30499067 DOI: 10.1007/S12325-018-0840-8  0.371
2018 Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A. Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 1076029618800806. PMID 30433823 DOI: 10.1177/1076029618800806  0.33
2018 Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. Journal of Managed Care & Specialty Pharmacy. 1-11. PMID 30212268 DOI: 10.18553/Jmcp.2018.17488  0.347
2018 Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. Plos One. 13: e0191722. PMID 29373602 DOI: 10.1371/Journal.Pone.0191722  0.357
2018 Amin A, Garcia AB, Li X, Dhamane A, Luo X, Fusco MD, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Baser O, Keshishian A. P6590Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in nonvalvular atrial fibrillation patients with heart failure European Heart Journal. 39. DOI: 10.1093/Eurheartj/Ehy566.P6590  0.334
2018 Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. P2903Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study European Heart Journal. 39: 612-613. DOI: 10.1093/Eurheartj/Ehy565.P2903  0.361
2018 Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. P2898Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study European Heart Journal. 39: 610-611. DOI: 10.1093/Eurheartj/Ehy565.P2898  0.34
2018 Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. P2568Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study European Heart Journal. 39: 505-505. DOI: 10.1093/Eurheartj/Ehy565.P2568  0.361
2018 Amin A, Garcia AB, Li X, Dhamane A, Luo X, Fusco MD, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Baser O, Keshishian A. P979Comparison of effectiveness, safety, and healthcare costs in non-valvular atrial fibrillation patients with heart failure prescribed direct oral anticoagulants European Heart Journal. 39. DOI: 10.1093/Eurheartj/Ehy564.P979  0.34
2018 Amin A, Keshishian A, Zhang Q, Dina O, Dhamane A, Nadkarni A, Carda E, Liu X, Rosenblatt L, Baser O, Baker C. P3844Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population European Heart Journal. 39. DOI: 10.1093/Eurheartj/Ehy563.P3844  0.347
2018 Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GY. COMPARISON OF EFFECTIVENESS, SAFETY, AND THE NET CLINICAL OUTCOME BETWEEN DIFFERENT DIRECT ORAL ANTICOAGULANTS IN 162,707 NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED IN US CLINICAL PRACTICE Journal of the American College of Cardiology. 71: A275. DOI: 10.1016/S0735-1097(18)30816-7  0.377
2017 Nadkarni A, McMorrow D, Patel C, Fowler R, Smith D. Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents. Journal of Comparative Effectiveness Research. PMID 28791875 DOI: 10.2217/Cer-2016-0090  0.369
2017 Nadkarni A, McMorrow D, Fowler R, Smith D. Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. Journal of Comparative Effectiveness Research. PMID 28791873 DOI: 10.2217/Cer-2017-0010  0.354
2017 Lin J, Trocio J, Gupta K, Mardekian J, Lingohr-Smith M, Menges B, You M, Nadkarni A. Major bleeding risk and healthcare economic outcomes of nonvalvular atrial fibrillation patients newly initiated with oral anticoagulant therapy in the real-world setting. Journal of Medical Economics. 1-23. PMID 28604139 DOI: 10.1080/13696998.2017.1341902  0.371
2017 Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GY. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. Thrombosis and Haemostasis. PMID 28300870 DOI: 10.1160/Th17-01-0068  0.36
2017 Li X, Lip G, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Deitelzweig S. P3603Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis European Heart Journal. 38. DOI: 10.1093/Eurheartj/Ehx504.P3603  0.368
2017 Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip G. P3588Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis European Heart Journal. 38. DOI: 10.1093/Eurheartj/Ehx504.P3588  0.356
2016 Rashid N, Lin AT, Aranda G, Lin KJ, Guerrero VN, Nadkarni A, Patel C. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. Journal of Medical Economics. 1-8. PMID 26766553 DOI: 10.3111/13696998.2016.1142448  0.378
2016 Deitelzweig S, Gupta K, Nadkarni A, Trocio J, Lin J, Lingohr-Smith M. HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN Journal of the American College of Cardiology. 67: 805. DOI: 10.1016/S0735-1097(16)30806-3  0.368
2015 Nadkarni A, You M, Resuehr H, Curtis JR. The Risk for Cardiovascular Events Associated with Hyperlipdemia among Patients with and Without Rheumatoid Arthritis. Journal of Arthritis. 4. PMID 26835182 DOI: 10.4172/2167-7921.1000178  0.324
2015 Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE. Patient-Reported Outcomes from a 2-year Head-to-Head Comparison of Subcutaneous Abatacept versus Adalimumab for Rheumatoid Arthritis. Arthritis Care & Research. PMID 26473625 DOI: 10.1002/Acr.22763  0.362
2015 Harrold LR, Gandhi KK, Etzel CJ, Nadkarni A, Saunders KC, Kelly S, Greenberg JD. OP0160 The Impact of Rheumatoid Arthritis on Patient Reported Outcomes and Quality of Life Prior to Biologic Initiation Annals of the Rheumatic Diseases. 74: 129-130. DOI: 10.1136/Annrheumdis-2015-Eular.2073  0.369
2015 Harrold LR, Gandhi KK, Etzel CJ, Nadkarni A, Saunders KC, Kelly S, Kremer JM. AB0468 Channeling of Biologic Agents: Comparing Baseline Characteristics of Biologic Naïve Rheumatoid Arthritis Patients Initiating Abatacept, as Compared to Other Biologic Agents and Small Molecule Agents Annals of the Rheumatic Diseases. 74: 1052-1053. DOI: 10.1136/Annrheumdis-2015-Eular.2068  0.352
2015 Thomson E, Nadkarni A, Brouillette M, Johnston S. AB0414 Real-World Cost of Treating Inadequate Responders to Anti-Tumour Necrosis Factor Therapy Annals of the Rheumatic Diseases. 74: 1032-1032. DOI: 10.1136/Annrheumdis-2015-Eular.1737  0.349
2015 Fowler R, McMorrow D, Smith D, Nadkarni A. FRI0364 Real-World Incidence of Biologic Dose Escalation and Impact on Biologic Costs Among Patients with Rheumatoid Arthritis Treated with Intravenous Agents Abatacept, Infliximab or Tocilizumab Annals of the Rheumatic Diseases. 74: 558-558. DOI: 10.1136/Annrheumdis-2015-Eular.1503  0.337
2015 Rashid N, Aranda G, Li Z, Guerrero V, Nadkarni A, Patel C. Factors and Reasons Associated With Switching In Rheumatoid Arthritis Patients Newly Initiated On Biologic Dmards And Impact on Health Care Resource Utilization In a Managed Care organization Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.889  0.306
2015 Rashid N, Patel C, Li Z, Guerrero V, Nadkarni A, Aranda G. Factors And Reasons Associated With Switching In Rheumatoid Arthritis Patients Experienced On Biologic Dmards And Impact On Health Care Resource Utilziation In An Integrated Healthcare System Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.888  0.33
2014 Citrome L, Johnston S, Nadkarni A, Sheehan JJ, Kamat SA, Kalsekar I. Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics. Current Drug Safety. 9: 227-35. PMID 24909573 DOI: 10.2174/1574886309666140601211551  0.336
2014 Hochberg M, Janssen K, Broglio K, Walsem AV, Nadkarni A. SAT0233 Comparison of Abatacept and Other Biologic DMARDS for the Treatment of Rheumatoid Arthritis Patients: A Systematic Literature Review and Network Meta-Analysis Annals of the Rheumatic Diseases. 73: 676-676. DOI: 10.1136/Annrheumdis-2014-Eular.5331  0.365
2014 Fleischmann R, Weinblatt M, Schiff M, Khanna D, Maldonado M, Nadkarni A, Fay J, Furst D. SAT0246 Correlation of Clinical Response with Patient-Reported Outcomes in the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: 2-Year Results Annals of the Rheumatic Diseases. 73: 681-682. DOI: 10.1136/Annrheumdis-2014-Eular.2113  0.317
2014 Nadkarni A, Lobo F, Juday T. AB1028 Rates of Switching and Healthcare Costs Associated with Switching Biological Disease-Modifying Antirheumatic Drugs in A Commercial Population: Evidence from Real-World Observational Studies Annals of the Rheumatic Diseases. 73: 1140-1140. DOI: 10.1136/Annrheumdis-2014-Eular.1139  0.387
2014 Nadkarni A, You M, Graham JP. Health Care Costs And Switching In Patients Initiating Biologic Disease Modifying Antirheumatic Drugs Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.264  0.301
2014 Johnston SS, McMorrow D, Fowler R, Smith D, Nadkarni A. Comparison Of Health Care Costs Between Rheumatoid Arthritis Patients Initiating First Or Second-Line Subcutaneous Abatacept, Adalimumab, Or Etancercept: A Difference-In-Difference Analysis Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.263  0.335
2013 Citrome L, Collins JM, Nordstrom BL, Rosen EJ, Baker R, Nadkarni A, Kalsekar I. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. The Journal of Clinical Psychiatry. 74: 1199-206. PMID 24434088 DOI: 10.4088/Jcp.13M08642  0.301
2013 Hochberg MC, Berry S, Broglio K, Rosenblatt L, Nadkarni A, Trivedi D, Hebden T. Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis. Current Medical Research and Opinion. 29: 1213-22. PMID 23745516 DOI: 10.1185/03007995.2013.813839  0.37
2013 Nadkarni A, Kalsekar I, You M, Forbes R, Hebden T. Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. Clinicoeconomics and Outcomes Research : Ceor. 5: 49-57. PMID 23378778 DOI: 10.2147/Ceor.S36526  0.316
2013 Hochberg M, Berry S, Broglio K, Nadkarni A, Rosenblatt L, Trivedi D, Hebden T. AB0552 Relative efficacy and tolerability of intravenous and subcutaneous abatacept compared with tumor necrosis factor inhibitors in rheumatoid arthritis patients with an inadequate response to conventional disease-modifying antirheumatic drugs Annals of the Rheumatic Diseases. 71: 670-670. DOI: 10.1136/Annrheumdis-2012-Eular.552  0.365
2011 Nadkarni A, Kucukarslan SN, Bagozzi RP, Yates JF, Erickson SR. Examining determinants of self management behaviors in patients with diabetes: an application of the Theoretical Model of Effortful Decision Making and Enactment. Patient Education and Counseling. 85: 148-53. PMID 21041057 DOI: 10.1016/J.Pec.2010.09.027  0.63
2010 Nadkarni A, Kucukarslan SN, Bagozzi RP, Yates JF, Erickson SR. A simple and promising tool to improve self-monitoring of blood glucose in patients with diabetes. Diabetes Research and Clinical Practice. 89: 30-7. PMID 20381890 DOI: 10.1016/J.Diabres.2010.03.011  0.631
2008 Kucukarslan SN, Nadkarni A. Evaluating medication-related services in a hospital setting using the disconfirmation of expectations model of satisfaction. Research in Social & Administrative Pharmacy : Rsap. 4: 12-22. PMID 18342819 DOI: 10.1016/J.Sapharm.2007.01.001  0.643
Show low-probability matches.